Alamar Biosciences, Inc. (ALMR)
| Market Cap | 1.87B |
| Revenue (ttm) | 87.16M +195.2% |
| Net Income | -43.49M |
| EPS | -3.69 |
| Shares Out | 69.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 272,586 |
| Open | 27.48 |
| Previous Close | 27.07 |
| Day's Range | 26.47 - 27.48 |
| 52-Week Range | 18.85 - 29.43 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 31.80 (+17.91%) |
| Earnings Date | Aug 10, 2026 |
About ALMR
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnosti... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ALMR stock is "Buy." The 12-month stock price target is $31.8, which is an increase of 17.91% from the latest price.
News
Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
Expanded panel advances the understanding of immune system across translational and clinical research in cancer, cardiovascular and metabolic diseases, autoimmune diseases and aging
Alamar Biosciences price target raised to $34 from $30 at TD Cowen
TD Cowen raised the firm’s price target on Alamar Biosciences (ALMR) to $34 from $30 and keeps a Buy rating on the shares. The firm adjusted targets in the tools…
Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026
FREMONT, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it...
Alamar teams with research universities to launch proteomics initiatives
Alamar Biosciences (ALMR) announced a partnership with research universities to launch a national-scale proteomics initiative using Alamar Biosciences’ NULISAseq Neuro 220 panel to accelerate biomarke...
Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases
National-scale initiative will profile ~21,000 plasma samples from 10,000 Alzheimer's Disease and Related Dementias (ADRD) participants using Alamar Biosciences' NULISAseq™ Neuro 220 panel. | Resultin...
Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer's Biomarker Profiling
Company to host scientific workshop featuring emerging eMTBR-Tau and BD-pTau217 research data for Alzheimer's disease detection and staging Company to host scientific workshop featuring emerging eMTBR...
Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer's Disease Research
eMTBR-Tau offers a non-invasive, blood-based measurement of the tau tangle burden, the core pathology associated with disease progression and cognitive decline in Alzheimer's disease | Immunoassay for...
Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics
NULISA™ DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices | Workflow extends NULISA into longitudin...
Alamar Biosciences Transcript: Bank of America Global Healthcare Conference 2026
A precision proteomics platform launched in 2024 has achieved rapid adoption, especially in neurology and Alzheimer's research, with strong revenue growth and industry-leading sales efficiency. Strategic priorities include expanding content, commercial reach, and moving toward clinical diagnostics, with FDA submission expected next year.
Alamar Biosciences Slides: FY 2026
Alamar Biosciences has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 12, 2026.
Alamar Biosciences initiated with an Outperform at Leerink
Leerink initiated coverage of Alamar Biosciences (ALMR) with an Outperform rating and $35 price target Core to the firm’s thesis is the differentiated, highly automated ARGO HT instrument, NULISA tech...
Alamar Biosciences initiated with a Neutral at BofA
BofA initiated coverage of Alamar Biosciences (ALMR) with a Neutral rating and $27 price target The emerging growth life science tools company with a cutting edge platform for the study…
Alamar Biosciences initiated with a Buy at TD Cowen
TD Cowen analyst Dan Brennan initiated coverage of Alamar Biosciences (ALMR) with a Buy rating and $30 price target The company’s Nulisa chemistry and “easy-to-use, robust” Argo platform offer a…
Alamar Biosciences initiated with an Overweight at JPMorgan
JPMorgan analyst Casey Woodring initiated coverage of Alamar Biosciences (ALMR) with an Overweight rating and $30 price target Alamar is a proteomics platform company with a nucleic acid linked immuno...
Alamar Biosciences initiated with a Buy at Stifel
Stifel initiated coverage of Alamar Biosciences (ALMR) with a Buy rating and $28 price target Alamar is an emerging multiplex proteomics player that has seen rapid adoption of its ARGO…
Alamar Biosciences reports Q1 EPS ($1.74) vs. (68c) last year
Reports Q1 revenue $26.04M vs. $13.09M last year. “We began 2026 with a record quarter, nearly doubling revenue year over year as our NULISA platform gained rapid global traction among…
Alamar Biosciences Earnings release: Q1 2026
Alamar Biosciences released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Alamar Biosciences Quarterly report: Q1 2026
Alamar Biosciences has published its Q1 2026 quarterly earnings report on May 8, 2026.
Alamar Biosciences Reports First Quarter 2026 Financial Results
FREMONT, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today reported fina...
Alamar Biosciences to Participate in BofA Securities 2026 Healthcare Conference
FREMONT, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it ...
Alamar Biosciences to Report First Quarter 2026 Financial Results on May 8, 2026
FREMONT, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced i...
Alamar Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
FREMONT, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (“Alamar”), a leader in Precision Proteomics dedicated to advancing the early detection of disease, today announced the clo...
Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ
SHANGHAI, April 20, 2026 /PRNewswire/ -- Alamar Biosciences, a portfolio company of Qiming Venture Partners and a global leader in precision proteomics, successfully listed on the NASDAQ Stock Exchang...
Cathie Wood’s ARK Investment buys 537.5K shares of Alamar Biosciences today
20:08 EDT Cathie Wood’s ARK Investment buys 537.5K shares of Alamar Biosciences (ALMR) today
Alamar Biosciences valued at $1.5 billion as shares jump in Nasdaq debut
Shares of Alamar Biosciences jumped 33% in their Nasdaq debut on Friday, valuing the protein biomarker detection platform at $1.53 billion.